TCT In Brief
This article was originally published in The Gray Sheet
Executive Summary
HORIZONS-AMI: Two-year follow-up results from the 3,000-patient randomized trial show that ischemia-driven target lesion revascularization - the primary endpoint of the study - was 6.8% in patients receiving Boston Scientific's Taxus Express stent compared to 11.6% for those treated with a bare metal stent, firm reports during the Transcatheter Cardiovascular Therapeutics conference in San Francisco. For the secondary endpoint, target vessel revascularization, the rates for the Taxus Express and bare metal stent groups were 8.9% and 13.3%, respectively. The rate of major adverse cardiac events at two years was 11% for the drug-eluting stent and 11.2% for the bare metal stent. HORIZONS-AMI is designed to assess the safety and efficacy of Taxus Express in high-risk acute myocardial infarction patients
You may also be interested in...
Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs
Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.